Barclays analyst Saket Kalia maintains Zscaler (NASDAQ:ZS) with a Equal-Weight and lowers the price target from $160 to $143.
Johnson & Johnson Medtech Business Has Promising Momentum, Analysts Say After Good Q2 Performance
Credit Suisse analyst Trung Huynh increased the price for Johnson & Johnson (NYSE: JNJ) to $175 from $170,